Top Decile[1] Fund Manager announces first close on second fund First closing at A$55m supported by Australian institutions IOOF provides $45m cornerstone Focused on clinical stage healthcare and life sciences firms First investment $3m into ASX Listed Avita (ASX.AVH) Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), today announced a successful first close on its […]
IB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital (NZX.CLA) in conjunction with Claridge’s acquisition of SeaDragon Marine Oils. The subscription arrangement is conditional upon the satisfaction of a number of commercial conditions. The […]
Octa Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of the appointment of Dr William (Bill) Hunter to its board. William Hunter co-founded Angiotech Pharmaceuticals in 1992 while still being a medical student at university. […]
New look Octa Phillip Bioscience Managers (Bioscience Managers – formerly IB Managers) is looking to create an all-star team with the addition of Starmine top rated analyst Dr Graeme Wald as it progresses towards a first close on its second fund. With its first fund’s performance confirmed in the top decile of global (2008 ex-US) […]